Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 15/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 10/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.68 |
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349191 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL20798009 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL27554036 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL20074354 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL12729520 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL16633413 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8003 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Water SCHEMBL3961110 | 0.99 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Bromide SCHEMBL18112592 | 0.99 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Iodide SCHEMBL7941539 | 0.99 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9157073-B1 | DNA polymerases | NEW ENGLAND BIOLABS, INC. (US) | 2015-10-13 | — | — | US | claimed |
| US-9127258-B2 | DNA polymerases | NEW ENGLAND BIOLABS, INC. (US) | 2015-09-08 | — | — | US | claimed |
| EP-2170924-B1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | LIFE TECHNOLOGIES CORP (US) | 2015-07-22 | — | — | EP | claimed |
| US-20150152396-A1 | Novel DNA Polymerases | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2015-06-04 | — | — | US | claimed |
| US-8993298-B1 | DNA polymerases | NEW ENGLAND BIOLABS, INC. (US) | 2015-03-31 | — | — | US | claimed |
| EP-2028272-B1 | METHOD OF MODIFYING NUCLEOTIDE CHAIN | PANASONIC CORP (JP) | 2014-01-08 | — | — | EP | claimed |
| US-20120252030-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | Life Technologies Corporation (US) | 2012-10-04 | — | — | US | claimed |
| US-20120135472-A1 | HOT-START PCR BASED ON THE PROTEIN TRANS-SPLICING OF NANOARCHAEUM EQUITANS DNA POLYMERASE | Research & Business Foundation Sungkyunkwan University (KR) | 2012-05-31 | — | — | US | claimed |
| US-7915392-B2 | 5-bromo-2′-deoxy-uridine labeled nucleotide triphosphates and nucleic acid probes and methods of making and using the same | Life Technologies Corporation (US) | 2011-03-29 | — | — | US | claimed |
| US-20100015670-A1 | METHOD OF MODIFYING NUCLEOTIDE CHAIN | PANASONIC CORPORATION (JP) | 2010-01-21 | — | — | US | claimed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | claimed |
| WO-2003055898-A1 | ENZYMATIC REDOX LABELLING OF NUCLEIC ACIDS | UNISEARCH LIMITED (AU) | 2003-07-10 | — | — | WO | claimed |
| US-6589742-B2 | Producing single stranded amplicon species for detection, using asymmetrical amplification rather than heat or chemical denaturation | NANOGEN, INC. | 2003-07-08 | — | — | US | claimed |
| EP-1025115-B1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE FLUORESCENT CONJUGATES, PREPARATION METHOD AND USES | CIS BIO INT (FR) | 2003-06-04 | — | — | EP | claimed |
| US-6531302-B1 | Using primer pair sets anchored to a microarray through capture sites or through a branched primer pair moiety; allows for simultaneous multiplex capture, amplification, and detection of a target nucleic acid | NANOGEN/BECTON DICKINSON PARTNERSHIP | 2003-03-11 | — | — | US | claimed |
| WO-2000060919-B1 | ANCHORED STRAND DISPLACEMENT AMPLIFICATION ON AN ELECTRONICALLY ADDRESSABLE MICROCHIP | NANOGEN BECTON DICKINSON PARTN (US) | 2002-01-31 | — | — | WO | claimed |
| US-6340747-B1 | COMPLEXED TO RARE EARTH METAL CRYPTATE LABEL; DETECTION AND ISOLATION OF NUCLEIC ACIDS | CIS BIO INTERNATIONAL (FR) | 2002-01-22 | — | — | US | claimed |
| US-6063604-A | SEPARATION OF TARGET NUCLEOTIDE SEQUENCE FOUND WITHIN A SINGLE-STRANDED POLYNUCLEOTIDE; PROVIDING A REACTION MIXTURE, SEPARATING NUCLEOTIDE SEQUENCES, ALLOWING HYBRIDIZATION, PRIMER EXTENSION AND BREAKING, AMPLIFY NUCLEOTIDES | MOLECULAR BIOLOGY RESOURCES, INC. (US) | 2000-05-16 | — | — | US | claimed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | claimed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252030-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | DUT, PCNA, TK1 | DUT 1/4885P2RY2 725/4885P2RY4 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.